CHWY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Chewy is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy, because the stock is technically weak and there is no proprietary buy signal today. The business fundamentals are improving and analysts remain broadly positive, but the current price action does not confirm an attractive entry. My direct view: hold off for now and do not buy at this level.
CHWY is in a short-term downtrend. The stock closed at 23.63, below the pivot at 24.929 and near support at 23.674, with the next support at 22.899. MACD histogram is negative and expanding, which confirms weakening momentum. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, showing the trend is still below recovery structure. RSI_6 at 22.422 is oversold, but not enough on its own to call a reversal. Overall, the chart says weak trend and no clear technical buy signal.
["Wolfe Research turned incrementally more positive after the Modern Animal acquisition, seeing upside in Chewy's Vet business and potential synergies.", "Several major firms remain Overweight/Buy/Outperform and raised or maintained relatively high price targets, including Morgan Stanley, RBC, Citi, Goldman Sachs, TD Cowen, and Citizens.", "Fiscal 2026 guidance was described by analysts as better than expected, supporting confidence in revenue and EBITDA growth.", "Latest quarter financials showed improving profitability: net income up 71.99% YoY, EPS up 80.00% YoY, and gross margin up 3.09% YoY.", "Free cash flow reportedly rose 24% year-over-year to $562 million, which supports long-term investment appeal."]
["The stock is trading below key moving averages and momentum remains negative.", "Regular market change was -3.74%, showing weak immediate price action.", "Hedge funds are selling, with selling increasing 382.78% over the last quarter.", "Insiders are selling heavily, with selling increasing 2640.37% over the last month.", "One major analyst, UBS, is Neutral and lowered its target to $32, showing some caution despite the overall bullish tone.", "Historical price pattern data suggests only limited upside near term, with a negative one-month expectation."]
In the latest reported quarter, Chewy posted revenue of $3.2647B, up 0.53% YoY, which shows modest top-line growth. More importantly, profitability improved sharply: net income rose 71.99% YoY to $39.2M, EPS increased 80.00% YoY to $0.09, and gross margin expanded to 29.4% from the prior year. The company’s recent fiscal-year commentary also pointed to 6% net sales growth for fiscal 2025 and 24% growth in free cash flow to $562M, indicating improving financial quality. Latest quarter season: 2026/Q4.
Analyst sentiment is broadly positive, with multiple firms maintaining Buy/Outperform/Overweight ratings and targets mostly in the $39-$49 range. Recent changes were mixed but generally constructive: Wolfe upgraded its tone after the Modern Animal deal, Morgan Stanley trimmed target slightly to $49 but stayed Overweight, RBC raised target to $47, Citi lowered to $40 but kept Buy, Goldman lowered to $46 but kept Buy, and TD Cowen raised to $42. The pros view is that Chewy is gaining share, improving margins, and has upside from Vet expansion and FCF growth. The cons view is that valuation and execution sensitivity still matter, and UBS’s Neutral stance at $32 shows not all analysts are convinced. Overall Wall Street view is favorable, but not enough to justify an urgent buy given the current weak technical setup.
